Michel Michaelides

To book an appointment please email Christian.Bonciarelli@moorfields.nhs.uk

Medical Retina (including diabetic retinopathy, retinal vein occlusions, and age-related macular degeneration).

Expertise in the use of Lucentis, Avastin and Eylea for the treatment of age-related macular degeneration and diabetic eye disease; and Photodynamic therapy (PDT) for selected retinal disorders including central serous retinopathy.

Inherited Eye Disease in adults and children (including Retinitis Pigmentosa, Stargardt macular dystrophy, Leber Congenital Amaurosis, Macular Dystrophies, Cone-Rod and Cone Dystrophies).

General Ophthalmology (including red eye).

• The John Saunders Suite
  Practice Manager - Christian Bonciarelli - 020 7566 2604

English and Greek

1997

King’s College London

King’s College Hospital
Moorfields Eye Hospital

Medical Retina Fellowship, Moorfields Eye Hospital
Ocular Genetics and Paediatric Ophthalmology Fellowships, Casey Eye Institute, Oregon, USA
Doctor of Medicine research degree in inherited retinal dystrophies from University College London

2005 – as a Registrar; 2010 – as a consultant

Fellow, Royal College of Ophthalmologists, London
Fellow of the American College of Surgeons
Member, American Academy of Ophthalmology
Member, Association for Research in Vision & Ophthalmology
Member, European Society of Retina Specialists
Member, European Paediatric Ophthalmological Society

Consultant Ophthalmic Surgeon, Moorfields Eye Hospital (2010)
Clinical Senior Lecturer in Ophthalmology, UCL Institute of Ophthalmology (2010)

Foundation Fighting Blindness (USA) Career Development Award (2011)
International Guest Scholar, American College of Surgeons (2010)
Department of Health/HEFCE ‘New Blood’ Senior Lectureship Award (2010)
Senior Resident, Moorfields Eye Hospital (2007)

New treatments for retinal disease including diabetic retinopathy and genetic eye disease such Retinitis Pigmentosa and Stargardt disease.
My long-term vision and goals include:
(i) Optimizing the clinical care of patients with retinal disease including:
(ii) Establishing a molecular genetic diagnosis in the majority of patients with inherited eye disease, helping to improve counseling, advice on prognosis, and identify patients with molecularly proven disease who may be eligible for current and future treatment trials.
(iii) Identify patients / genetic subtypes and time-points, which may be most appropriate for treatments, and identify reliable and sensitive outcome measures.
(iv) Assisting in the development of gene- and non-gene directed therapies to either significantly slow / halt disease progression or ideally improve visual function and subsequently being the clinical lead in undertaking rigorous clinical trials to ascertain their efficacy.

http://www.ucl.ac.uk/ioo/genetics/gene-and-cell-therapy/research-team

https://www.researchgate.net/profile/Michel_Michaelides/reputation/?ev=prf_rep_tab

Travel, Scuba Diving and Swimming